Hepatitis B vaccine using SBAS4 adjuvant: Phase III

A total of 98 percent of 120 patients unresponsive to Engerix-B seroconverted after three doses of the improved vaccine, compared to 81 percent who seroconverted after the third dose of Engerix-B. The vaccines were given at 0, 1 and 6 months. ...